Our investigation demonstrated that administration of DPP-4 inhibitors in individuals afflicted with T2DM does not notably elevate the cardiac risk within this demographic, inclusive of MI, MACE, HF, and all-cause mortality as well as stroke events. The gene discussed is DPP4; the disease is stroke disorder.